1. Scrip

Korea Q4 Roundup: GC’s IVIG US Approval, SK Biopharm Turns Around

Hanmi May Face Shareholders' Vote

 
• By Jung Won Shin

Aside from mixed earnings at major South Korean pharma firms, recent updates across the local industry have included the ongoing leadership dispute at Hanmi Group, the approval and reimbursement of Yuhan’s lazertinib as a first-line NSCLC therapy and the US approval of GC Biopharma’s immuno-globulin product.

earnings
Yuhan's Lazertinib Reimbursed, Approved As 1L NSCLC Therapy • Source: Shutterstock

Major South Korean pharma firms reported largely mixed results in the fourth quarter amid a range of factors such as license deal-related income, robust sales of in-house developed prescription drugs and high margin products and solid overseas sales, as well as increased R&D spending as they focus more on innovative drug development.

Aside from earnings, an update in the dispute among members of the family of the late founder of Hanmi Pharmaceutical Group, wider approval and reimbursement of Yuhan Corporation’s Leclaza (lazertinib), as well as US approval of

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

More from Focus On Asia